BCMA/CD19-targeted allogeneic CAR-T is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 1. The sponsor with the most trials is Tianjin Medical University Cancer Institute and Hospital (1). The most-studied condition is Newly Diagnosed Multiple Myeloma (NDMM).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
NCT07652138 · ClinicalTrials.gov ↗ · Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | China |
|
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
NCT07114432 · ClinicalTrials.gov ↗ · Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1 | Not yet open | Tianjin Medical University Cancer Institute and Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name BCMA/CD19-targeted allogeneic CAR-T (also registered as RN1201) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tianjin Medical University Cancer Institute and Hospital (1) and The First Affiliated Hospital of Soochow University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BCMA/CD19-targeted allogeneic CAR-T works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BCMA/CD19-targeted allogeneic CAR-T works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BCMA/CD19-targeted allogeneic CAR-T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.